Company insight Advancing 3D
vonik is further expanding its portfolio of 3D-printable biomaterials for medical technology. The specialty chemicals company has developed VESTAKEEP iC4800 3DF, a new osteoconductive PEEK filament that improves fusion between bone and implants. The high-performance polymer can be processed in common extrusion- based 3D printing technologies, such as fused filament fabrication (FFF).
Quality of life
The new PEEK filament is a biomaterial from Evonik’s VESTAKEEP Fusion product line launched in 2020. The high- performance polymer impresses with excellent biocompatibility and biostability as well as improved osteoconductive properties. The osteoconductivity was achieved by using a functional special additive – biphasic calcium phosphate (BCP). The BCP additive allows bone cells to adhere to implants more quickly, thus positively influencing the boundary, so called osteointegration, between the bone and the implant. This, in turn, will accelerate bone fusion and patient recovery. VESTAKEEP iC4800 3DF was developed for use in the Fused Filament Fabrication (FFF) technology. With a
printable biomaterials E
Speciality chemicals company Evonik launches the osteoconductive VESTAKEEP Fusion PEEK fi lament for 3D printed implants, further expanding its portfolio of 3D-printable biomaterials.
VESTAKEEP Fusion polymers impress with excellent biocompatibility and biostability.
iC4800 3DF has been specially designed so that the functional additives are available directly on the surface of the 3D printed implant without further post-processing steps – a novelty for osteointegrative PEEK biomaterials. Like all products of the Fusion range, VESTAKEEP iC4800 is manufactured under strict quality management for biomaterials.
“No other application fi eld showcases more the classic advantages of 3D printing, such as individualisation or design freedom, than medical technology.”
Marc Knebel, Evonik
diameter of 1.75mm, the PEEK filament in natural colour is wound onto 250g or 500g spools. They can be used directly in standard FFF 3D printers for PEEK materials. Tests on various 3D printers as well as customer feedback confirm excellent processability of Evonik’s new filament. Furthermore, VESTAKEEP
Advanced 3D printing “No other application field showcases more the classic advantages of 3D printing, such as individualisation or design freedom, than medical technology,” says Marc Knebel, head of medical systems at Evonik. “Since the product launch of the first
Medical Device Developments /
www.nsmedicaldevices.com
PEEK filament a good three years ago, we have been expanding the possibilities of modern medical technology in the individual treatment of patients using additive manufacturing by constantly developing new innovative biomaterials.” Evonik has been the world’s leading manufacturer of high-performance polymers for additive manufacturing technologies for more than 20 years. The speciality chemicals company offers the industry’s most extensive portfolio of 3D-printable biomaterials for medical technology, which can be used to manufacture medical device parts designed for temporary and permanent body contact.
In addition to VESTAKEEP i4 3DF and VESTAKEEP Care M40 3DF, Evonik’s extensive portfolio includes the RESOMER line of bioresorbable filaments, powders and granules for a wide range of implantable medical devices. ●
www.evonik.com/medical-technology 113
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170
